Посилання

Перелік літератури

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Повний текст  Резюме

2. World Health Organization. Clinical management of COVID-19: interim guidance. 2020 [internet publication].Повний текст

3. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020 [internet publication].Повний текст

4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Повний текст  Резюме

5. Colaneri M, Sacchi P, Zuccaro V, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 2020 Apr;25(16).Повний текст  Резюме

6. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Повний текст  Резюме

7. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Повний текст  Резюме

8. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2020 Sep 25 [Epub ahead of print].Повний текст  Резюме

9. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Повний текст  Резюме

10. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Повний текст  Резюме

11. Brambilla I, Castagnoli R, Caimmi S, et al. COVID-19 in the pediatric population admitted to a tertiary referral hospital in Northern Italy: preliminary clinical data. Pediatr Infect Dis J. 2020 Jul;39(7):e160.Повний текст  Резюме

12. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020 Apr 14;323(14):1335.Повний текст  Резюме

13. Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020 Apr 8 [Epub ahead of print].Повний текст  Резюме

14. American Academy of Pediatrics. Children and COVID-19: state-level data report. 2020 [internet publication].Повний текст

15. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020 Aug 27;370:m3249.Повний текст  Резюме

16. Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. Clin Infect Dis. 2020 May 11 [Epub ahead of print].Повний текст  Резюме

17. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Apr 22 [Epub ahead of print].Повний текст  Резюме

18. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Jul 3:100446.Повний текст  Резюме

19. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020 Jun 8;369:m2107.Повний текст  Резюме

20. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22 – June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):769-75.Повний текст  Резюме

21. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in healthcare workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2020 Sep 1 [Epub ahead of print].Повний текст  Резюме

22. Sahu AK, Amrithanand VT, Mathew R, et al. COVID-19 in health care workers: a systematic review and meta-analysis. Am J Emerg Med. 2020 Jun 6;38(9):1727-31.Повний текст  Резюме

23. Torjesen I. Covid-19: one in 10 cases in England occurred in frontline health and social care staff. BMJ. 2020 Jul 7;370:m2717.Повний текст  Резюме

24. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, et al. Prevalence and clinical presentation of health care workers with symptoms of coronavirus disease 2019 in 2 Dutch hospitals during an early phase of the pandemic. JAMA Netw Open. 2020 May 1;3(5):e209673.Повний текст  Резюме

25. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19: United States, February 12 –April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-81.Повний текст  Резюме

26. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Повний текст  Резюме

27. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Повний текст  Резюме

28. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Повний текст  Резюме

29. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Review. 2020 Mar 3 [Epub ahead of print].Повний текст

30. Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020 Aug 18 [Epub ahead of print].Повний текст  Резюме

31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Повний текст  Резюме

32. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Повний текст  Резюме

33. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Повний текст  Резюме

34. Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020 Jan 29;79:104212. Резюме

35. Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr;92(4):433-40.Повний текст  Резюме

36. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020 Apr 6;30(7):1346-51.Повний текст  Резюме

37. Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020 Jul;583(7815):282-5.Повний текст  Резюме

38. Mallapaty S. Animal source of the coronavirus continues to elude scientists. Nature. 2020 May 18 [Epub ahead of print].Повний текст  Резюме

39. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2020 Sep 17 [Epub ahead of print].Повний текст  Резюме

40. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions – scientific brief. 2020 [internet publication].Повний текст

41. Centers for Disease Control and Prevention. How COVID-19 spreads. 2020 [internet publication].Повний текст

42. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564-7.Повний текст  Резюме

43. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7).Повний текст  Резюме

44. Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. Clin Infect Dis. 2020 Jul 8 [Epub ahead of print].Повний текст  Резюме

45. Colaneri M, Seminari E, Novati S, et al. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clin Microbiol Infect. 2020 Aug;26(8):1094.e1-5.Повний текст  Резюме

46. Colaneri M, Seminari E, Piralla A, et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. J Hosp Infect. 2020 Mar 19 [Epub ahead of print].Повний текст  Резюме

47. van Doorn AS, Meijer B, Frampton CMA, et al. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther. 2020 Aug 27 [Epub ahead of print].Повний текст  Резюме

48. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Dec;9(1):386-9.Повний текст  Резюме

49. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-3.Повний текст  Резюме

50. Centre for Evidence-Based Medicine; Ferner RE, Murray PI, Aronson JK. Spreading SARS-CoV-2 through ocular fluids. 2020 [internet publication].Повний текст

51. Sun T, Guan J. Novel coronavirus and central nervous system. Eur J Neurol. 2020 Mar 26 [Epub ahead of print].Повний текст  Резюме

52. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology. 2020 Jul;127(7):977-9.Повний текст  Резюме

53. Farina A, Uccello G, Spreafico M, et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med. 2020 Jun;76:100-1.Повний текст  Резюме

54. Algarroba GN, Rekawek P, Vahanian SA, et al. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. Am J Obstet Gynecol. 2020 Aug;223(2):275-8.Повний текст  Резюме

55. Li D, Jin M, Bao P, et al. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Netw Open. 2020 May 1;3(5):e208292.Повний текст  Резюме

56. Mei F, Bonifazi M, Menzo S, et al. First detection of SARS-CoV-2 by real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay in pleural fluid. Chest. 2020 Jun 11 [Epub ahead of print].Повний текст  Резюме

57. Kashi AH, De la Rosette J, Amini E, et al. Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies. Urol J. 2020 Sep 5 [Epub ahead of print].Повний текст  Резюме

58. Frazier KM, Hooper JE, Mostafa HH, et al. SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery. JAMA Otolaryngol Head Neck Surg. 2020 Jul 23 [Epub ahead of print].Повний текст  Резюме

59. Yan Y, Diao B, Liu Y, et al. Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein in the ocular tissues of a patient previously infected with coronavirus disease 2019. JAMA Ophthalmol. 2020 Oct 8 [Epub ahead of print].Повний текст  Резюме

60. Kotlyar A, Grechukhina O, Chen A, et al. Vertical transmission of COVID-19: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Jul 30 [Epub ahead of print].Повний текст  Резюме

61. Walker KF, O'Donoghue K, Grace N, et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. BJOG. 2020 Jun 12 [Epub ahead of print].Повний текст  Резюме

62. Groß R, Conzelmann C, Müller JA, et al. Detection of SARS-CoV-2 in human breastmilk. Lancet. 2020 Jun 6;395(10239):1757-8.Повний текст  Резюме

63. Tam PCK, Ly KM, Kernich ML, et al. Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020 May 30 [Epub ahead of print].Повний текст  Резюме

64. Costa S, Posteraro B, Marchetti S, et al. Excretion of Sars-Cov-2 in human breastmilk samples. Clin Microbiol Infect. 2020 Jun 2 [Epub ahead of print].Повний текст  Резюме

65. Salvatore CM, Han JY, Acker KP, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. Lancet Child Adolesc Health. 2020 Jul 23 [Epub ahead of print].Повний текст  Резюме

66. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Повний текст  Резюме

67. Rickman HM, Rampling T, Shaw K, et al. Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. Clin Infect Dis. 2020 Jun 20 [Epub ahead of print].Повний текст  Резюме

68. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Повний текст  Резюме

69. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Повний текст  Резюме

70. Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. 2020 [internet publication].Повний текст

71. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. Emerg Infect Dis. 2020 May 17;26(5).Повний текст  Резюме

72. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Повний текст  Резюме

73. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Повний текст  Резюме

74. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2020 Mar 19 [Epub ahead of print].Повний текст  Резюме

75. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Повний текст  Резюме

76. Du Z, Xu X, Wu Y, et al. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020 Mar 19;26(6).Повний текст  Резюме

77. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic transmission of SARS-CoV-2: Singapore, January 23 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-5.Повний текст  Резюме

78. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Повний текст  Резюме

79. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Повний текст  Резюме

80. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. Ann Intern Med. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

81. World Health Organization. Advice on the use of masks in the context of COVID-19: interim guidance. 2020 [internet publication].Повний текст

82. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Повний текст  Резюме

83. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Повний текст  Резюме

84. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Повний текст  Резюме

85. He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020 Jul 21 [Epub ahead of print].Повний текст  Резюме

86. Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. Int J Infect Dis. 2020 Jul 2;98:372-80.Повний текст  Резюме

87. Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10).Повний текст  Резюме

88. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 2020 Mar 23;368:m1165.Повний текст  Резюме

89. Centre for Evidence-Based Medicine; Heneghan C, Brassey J, Jefferson T. COVID-19: What proportion are asymptomatic? 2020 [internet publication].Повний текст

90. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020 Jun 3 [Epub ahead of print].Повний текст  Резюме

91. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility: King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-81.Повний текст  Резюме

92. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 May 28;382(22):2081-90.Повний текст  Резюме

93. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020 Sep;17(9):e1003346.Повний текст  Резюме

94. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients – Nashville, Tennessee. Clin Infect Dis. 2020 Jul 6 [Epub ahead of print].Повний текст  Резюме

95. Vahidy FS, Bernard DW, Boom ML, et al. Prevalence of SARS-CoV-2 infection among asymptomatic health care workers in the Greater Houston, Texas, area. JAMA Netw Open. 2020 Jul 1;3(7):e2016451.Повний текст  Резюме

96. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Jun;20(6):689-96.Повний текст  Резюме

97. Zheng B, Wang H, Yu C. An increasing public health burden arising from children infected with SARS-CoV2: a systematic review and meta-analysis. Pediatr Pulmonol. 2020 Aug 5 [Epub ahead of print].Повний текст  Резюме

98. Milani GP, Bottino I, Rocchi A, et al. Frequency of children vs adults carrying severe acute respiratory syndrome coronavirus 2 asymptomatically. JAMA Pediatr. 2020 Sep 14 [Epub ahead of print].Повний текст  Резюме

99. Frieden TR, Lee CT. Identifying and interrupting superspreading events: implications for control of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020 Jun;26(6):1059-66.Повний текст  Резюме

100. Schwartz NG, Moorman AC, Makaretz A, et al. Adolescent with COVID-19 as the source of an outbreak at a 3-week family gathering: four states, June–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 5 [Epub ahead of print].Повний текст  Резюме

101. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Повний текст  Резюме

102. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships: worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-52.Повний текст  Резюме

103. Yang H, Thompson JR. Fighting covid-19 outbreaks in prisons. BMJ. 2020 Apr 2;369:m1362.Повний текст  Резюме

104. Rogers JH, Link AC, McCulloch D, et al. Characteristics of COVID-19 in homeless shelters: a community-based surveillance study. Ann Intern Med. 2020 Sep 15 [Epub ahead of print].Повний текст  Резюме

105. Centre for Evidence-Based Medicine; Durand-Moreau Q, Adisesh A, Mackenzie G, et al. What explains the high rate of SARS-CoV-2 transmission in meat and poultry facilities? 2020 [internet publication].Повний текст

106. Donahue M, Sreenivasan N, Stover D, et al. Notes from the field: characteristics of meat processing facility workers with confirmed SARS-CoV-2 infection – Nebraska, April-May 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1020-2.Повний текст  Резюме

107. Steinberg J, Kennedy ED, Basler C, et al. COVID-19 outbreak among employees at a meat processing facility: South Dakota, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1015-9.Повний текст  Резюме

108. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Повний текст  Резюме

109. Leeb RT, Price S, Sliwa S, et al. COVID-19 trends among school-aged children: United States, March 1–September 19, 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1410-5.Повний текст  Резюме

110. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Повний текст  Резюме

111. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Повний текст  Резюме

112. McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020 Aug 16;10(8):e039652.Повний текст  Резюме

113. Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13;27(2).Повний текст  Резюме

114. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Повний текст  Резюме

115. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2020 [internet publication].Повний текст

116. Inglesby TV. Public health measures and the reproduction number of SARS-CoV-2. JAMA. 2020 May 1 [Epub ahead of print].Повний текст  Резюме

117. Koh WC, Naing L, Chaw L, et al. What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One. 2020 Oct 8;15(10):e0240205.Повний текст  Резюме

118. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 6;69(9):245-6.Повний текст  Резюме

119. Cheng HY, Jian SW, Liu DP, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 May 1 [Epub ahead of print].Повний текст  Резюме

120. Zhang W, Cheng W, Luo L, et al. Secondary transmission of coronavirus disease from presymptomatic persons, China. Emerg Infect Dis. 2020 May 26;26(8).Повний текст  Резюме

121. Yung CF, Kam KQ, Chong CY, et al. Household transmission of SARS-CoV-2 from adults to children. J Pediatr. 2020 Jul 4 [Epub ahead of print].Повний текст  Резюме

122. Macartney K, Quinn HE, Pillsbury AJ, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child Adolesc Health. 2020 Aug 3 [Epub ahead of print].Повний текст  Резюме

123. Ra SH, Lim JS, Kim GU, et al. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. 2020 Sep 22 [Epub ahead of print].Повний текст  Резюме

124. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-62.Повний текст  Резюме

125. Chang, Mo G, Yuan X, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med. 2020 May 1;201(9):1150-2.Повний текст  Резюме

126. Yang JR, Deng DT, Wu N, et al. Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection. J Med Virol. 2020 Apr 24 [Epub ahead of print]. Резюме

127. Jiang X, Luo M, Zou Z, et al. Asymptomatic SARS-CoV-2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days. J Med Virol. 2020 Apr 24 [Epub ahead of print]. Резюме

128. Li J, Zhang L, Liu B, et al. Case report: viral shedding for 60 days in a woman with novel coronavirus disease (COVID-19). Am J Trop Med Hyg. 2020 Jun;102(6):1210-3.Повний текст  Резюме

129. Sun J, Xiao J, Sun R, et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis. 2020 May 8;26(8).Повний текст  Резюме

130. Molina LP, Chow SK, Nickel A, et al. Prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in an obstetric patient with antibody seroconversion. Obstet Gynecol. 2020 Jul 21 [Epub ahead of print].Повний текст  Резюме

131. Noh JY, Yoon JG, Seong H, et al. Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration. J Infect. 2020 May 20 [Epub ahead of print].Повний текст  Резюме

132. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January – March 2020: retrospective cohort study. BMJ. 2020 Apr 21;369:m1443.Повний текст  Резюме

133. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Повний текст  Резюме

134. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020 Jul 28;71(15):799-806.Повний текст  Резюме

135. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8.Повний текст  Резюме

136. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Повний текст  Резюме

137. Hanff TC, Harhay MO, Brown TS, et al. Is there an association between COVID-19 mortality and the renin-angiotensin system: a call for epidemiologic investigations. Clin Infect Dis. 2020 Jul 28;71(15):870-4.Повний текст  Резюме

138. Wu Z, Hu R, Zhang C, et al. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care. 2020 Jun 5;24(1):290.Повний текст  Резюме

139. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Apr;14(2):185-92.Повний текст  Резюме

140. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020 May 20;323(23):2427-9.Повний текст  Резюме

141. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Повний текст  Резюме

142. Bunyavanich S, Grant C, Vicencio A. Racial/ethnic variation in nasal gene expression of transmembrane serine protease 2 (TMPRSS2). JAMA. 2020 Sep 10 [Epub ahead of print].Повний текст  Резюме

143. Piplani S, Singh PK, Winkler DA, et al; arXiv. In silico comparison of spike protein-ACE2 binding affinities across species; significance for the possible origin of the SARS-CoV-2 virus. 2020 [internet publication].Повний текст

144. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Резюме

145. Menter T, Haslbauer JD, Nienhold R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020 May 4 [Epub ahead of print].Повний текст  Резюме

146. Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA. 2020 May 21;323(24):2518-20.Повний текст  Резюме

147. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 May 14 [Epub ahead of print].Повний текст  Резюме

148. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-8.Повний текст  Резюме

149. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020 Jul;8(7):681-6.Повний текст  Резюме

150. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020 Jun 8 [Epub ahead of print].Повний текст  Резюме

151. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med. 2020 Jun 12 [Epub ahead of print].Повний текст  Резюме

152. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Oct 5 [Epub ahead of print].Повний текст  Резюме

153. Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020 Jul 27 [Epub ahead of print].Повний текст  Резюме

154. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health. 2020 Aug 20 [Epub ahead of print].Повний текст  Резюме

155. Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020 Sep 25 [Epub ahead of print].Повний текст  Резюме

156. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Aug 20 [Epub ahead of print].Повний текст  Резюме

157. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020 May 11;9(5): E1417.Повний текст  Резюме

158. Tibiriçá E, De Lorenzo A. Increased severity of COVID-19 in people with obesity: are we overlooking plausible biological mechanisms? Obesity (Silver Spring). 2020 May 13 [Epub ahead of print].Повний текст  Резюме

159. Bermejo-Martin JF, Almansa R, Torres A, et al. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020 Aug 1;116(10):e132-3.Повний текст  Резюме

160. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020 Aug;7(8):e575-82.Повний текст  Резюме

161. Maier CL, Truong AD, Auld SC, et al. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet. 2020 Jun 6;395(10239):1758-9.Повний текст  Резюме

162. van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020 Jul 24;324(7):1-11.Повний текст  Резюме

163. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 [internet publication].Повний текст

164. Shen N, Zhu Y, Wang X, et al. Characteristics and diagnosis rate of 5,630 subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan, China. JCI Insight. 2020 May 21;5(10):e137662.Повний текст  Резюме

165. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 May 15 [Epub ahead of print].Повний текст  Резюме

166. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): older adults. 2020 [internet publication].Повний текст

167. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people who are at higher risk for severe illness. 2020 [internet publication].Повний текст

168. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Повний текст  Резюме

169. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Повний текст  Резюме

170. Iacobucci G. Covid-19: Nearly half of care homes in northeast England have had an outbreak. BMJ. 2020 May 20;369:m2041.Повний текст  Резюме

171. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Повний текст  Резюме

172. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Повний текст  Резюме

173. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. 2020 Aug;31(8):1040-5.Повний текст  Резюме

174. Zeng F, Dai C, Cai P, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020 May 8 [Epub ahead of print].Повний текст  Резюме

175. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020 Aug 19 [Epub ahead of print].Повний текст

176. Raisi-Estabragh Z, McCracken C, Bethell MS, et al. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J Public Health (Oxf). 2020 Aug 18;42(3):451-60.Повний текст  Резюме

177. Hull SA, Williams C, Ashworth M, et al. Prevalence of suspected COVID-19 infection in patients from ethnic minority populations: a cross-sectional study in primary care. Br J Gen Pract. 2020 Sep 7 [Epub ahead of print].Повний текст  Резюме

178. Alaa AM, Qian Z, Rashbass J, et al. Ethnicity and outcomes of COVID-19 patients in England. 2020 [internet publication].Повний текст

179. Harrison EM, Docherty AB, Barr B, et al; SSRN. Ethnicity and outcomes from COVID-19: the ISARIC CCP-UK prospective observational cohort study of hospitalised patients. 2020 [internet publication].Повний текст

180. Centers for Disease Control and Prevention. COVIDView: a weekly surveillance summary of US COVID-19 activity. 2020 [internet publication].Повний текст

181. Yehia BR, Winegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020 Aug 3;3(8):e2018039.Повний текст  Резюме

182. Kabarriti R, Brodin NP, Maron MI, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. JAMA Netw Open. 2020 Sep 1;3(9):e2019795.Повний текст  Резюме

183. Wortham JM, Lee JT, Althomsons S, et al. Characteristics of persons who died with COVID-19: United States, February 12 – May 18, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):923-9.Повний текст  Резюме

184. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Повний текст  Резюме

185. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. 2020 [internet publication].Повний текст

186. Mahumud RA, Kamara JK, Renzaho AMN. The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis. Infection. 2020 Aug 19;1-21.Повний текст  Резюме

187. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance: United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-65.Повний текст  Резюме

188. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Повний текст  Резюме

189. CDC COVID-19 Response Team. Coronavirus disease 2019 in children: United States, February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-6.Повний текст  Резюме

190. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Повний текст  Резюме

191. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Повний текст  Резюме

192. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Curr Probl Cardiol. 2020 Apr 28:100617.Повний текст  Резюме

193. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Повний текст  Резюме

194. Zhang J, Wu J, Sun X, et al. Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol Infect. 2020 May 28;:1-19. Резюме

195. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 Aug 26 [Epub ahead of print].Повний текст  Резюме

196. Du Y, Lv Y, Zha W, et al. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2020 Sep 16:154373.Повний текст  Резюме

197. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020 Aug 12 [Epub ahead of print].Повний текст  Резюме

198. Savasi VM, Parisi F, Patanè L, et al. Clinical findings and disease severity in hospitalized pregnant women with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020 Aug;136(2):252-8.Повний текст  Резюме

199. Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr. 2020 Jun 3:e202430.Повний текст  Резюме

200. Hussain S, Baxi H, Chand Jamali M, et al. Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence. Diabetes Metab Syndr. 2020 Aug 20;14(6):1595-602.Повний текст  Резюме

201. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020 Apr 17;14(4):395-403.Повний текст  Резюме

202. Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. Diabetes Care. 2020 Aug 26 [Epub ahead of print].Повний текст  Резюме

203. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Повний текст  Резюме

204. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

205. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Повний текст  Резюме

206. Agarwal S, Schechter C, Southern W, et al. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. Diabetes Care. 2020 Aug 7 [Epub ahead of print].Повний текст  Резюме

207. Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care. 2020 Aug 11 [Epub ahead of print].Повний текст  Резюме

208. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: a meta-analysis of observational studies. Diabetes Obes Metab. 2020 Sep 1 [Epub ahead of print].Повний текст  Резюме

209. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

210. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020 May 29 [Epub ahead of print].Повний текст  Резюме

211. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Повний текст  Резюме

212. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Повний текст  Резюме

213. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Повний текст

214. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020 Jun;167:105941.Повний текст  Резюме

215. Wang Y, Chen J, Chen W, et al. Does asthma increase the mortality of patients with COVID-19? A systematic review and meta-analysis. Int Arch Allergy Immunol. 2020 Sep 22;:1-7.Повний текст  Резюме

216. Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 hospitalizations: an overestimated risk factor? Ann Am Thorac Soc. 2020 Aug 31 [Epub ahead of print].Повний текст  Резюме

217. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Jun 18 [Epub ahead of print].Повний текст  Резюме

218. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Повний текст  Резюме

219. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Повний текст  Резюме

220. Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int J Cancer. 2020 Jul 19 [Epub ahead of print].Повний текст  Резюме

221. Ofori-Asenso R, Ogundipe O, Agyeman AA, et al. Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. Ecancermedicalscience. 2020 May 18;14:1047.Повний текст  Резюме

222. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 May 29;21(7):893-903.Повний текст  Резюме

223. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol. 2020 Jun;6:799-808.Повний текст  Резюме

224. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

225. Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020 Aug 24 [Epub ahead of print].Повний текст  Резюме

226. Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020 Jul 28;14(5):1431-7.Повний текст  Резюме

227. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020 Jun;10(6):783-91.Повний текст  Резюме

228. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-18.Повний текст  Резюме

229. Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020 Jun 20;395(10241):1919-26.Повний текст  Резюме

230. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 May 29;21(7):904-13.Повний текст  Резюме

231. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

232. Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020 Sep 2;139:43-50.Повний текст  Резюме

233. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Повний текст  Резюме

234. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Повний текст  Резюме

235. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Повний текст  Резюме

236. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020 Jul;20(7):1800-8.Повний текст  Резюме

237. Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020 Jun;77(6):748-54.Повний текст  Резюме

238. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-7.Повний текст  Резюме

239. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol. 2020 Jun;31(6):1150-6.Повний текст  Резюме

240. Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020 Jun;97(6):1076-82.Повний текст  Резюме

241. Latif F, Farr MA, Clerkin KJ, et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiol. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

242. Fraser J, Mousley J, Testro A, et al. Clinical presentation, treatment, and mortality rate in liver transplant recipients with coronavirus disease 2019: a systematic review and quantitative analysis. Transplant Proc. 2020 Jul 30 [Epub ahead of print].Повний текст  Резюме

243. Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2020 Aug 4 [Epub ahead of print].Повний текст  Резюме

244. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Повний текст  Резюме

245. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication].Повний текст

246. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2020 Aug 8 [Epub ahead of print].Повний текст  Резюме

247. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Повний текст

248. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Jul 28 [Epub ahead of print].Повний текст  Резюме

249. Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Jun 8 [Epub ahead of print].Повний текст  Резюме

250. Pan L, Huang P, Xie X, et al. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2020 Sep 17 [Epub ahead of print].Повний текст  Резюме

251. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Повний текст  Резюме

252. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Повний текст  Резюме

253. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12 [Epub ahead of print].Повний текст  Резюме

254. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Повний текст  Резюме

255. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Повний текст  Резюме

256. Singh S, Khan A, Chowdhry M, et al. Risk of severe COVID-19 in patients with inflammatory bowel disease in United States: a multicenter research network study. Gastroenterology. 2020 Jun 6 [Epub ahead of print].Повний текст  Резюме

257. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Повний текст  Резюме

258. Meltzer DO, Best TJ, Zhang H, et al. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open. 2020 Sep 1;3(9):e2019722.Повний текст  Резюме

259. Lau FH, Majumder R, Torabi R, et al; medRxiv. Vitamin D insufficiency is prevalent in severe COVID-19. 2020 [internet publication].Повний текст

260. Rhodes JM, Subramanian S, Laird E, et al. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther. 2020 Jun;51(12):1434-7.Повний текст  Резюме

261. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? Med Drug Discov. 2020 Apr 29:100041.Повний текст  Резюме

262. Israel A, Cicurel A, Feldhamer I, et al; medRxiv. The link between vitamin D deficiency and Covid-19 in a large population. 2020 [internet publication].Повний текст

263. Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020 Jul 23 [Epub ahead of print].Повний текст  Резюме

264. Maghbooli Z, Sahraian MA, Ebrahimi M, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One. 2020 Sep 25;15(9):e0239799.Повний текст  Резюме

265. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Повний текст

266. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: A systematic review. Environ Res. 2020 Aug 24;191:110129.Повний текст  Резюме

267. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Повний текст  Резюме

268. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Повний текст  Резюме

269. Wu X, Nethery RC, Sabath BM, et al; medRxiv. Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study. 2020 [internet publication].Повний текст

270. Sajadi MM, Habibzadeh P, Vintzileos A, et al. Temperature, humidity, and latitude analysis to estimate potential spread and seasonality of coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020 Jun 1;3(6):e2011834.Повний текст  Резюме

271. Centre for Evidence-Based Medicine; Spencer EA, Brassey J, Jefferson T, et al. Environmental weather conditions and influence on transmission of SARS-CoV-2. 2020 [internet publication].Повний текст

272. Mecenas P, Bastos RTDRM, Vallinoto ACR, et al. Effects of temperature and humidity on the spread of COVID-19: a systematic review. PLoS One. 2020;15(9):e0238339.Повний текст  Резюме

273. Yao Y, Pan J, Liu Z, et al. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020 May 7;55(5):2000517.Повний текст  Резюме

274. Baker RE, Yang W, Vecchi GA, et al. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science. 2020 Jul 17;369(6501):315-9.Повний текст  Резюме

275. Sehra ST, Salciccioli JD, Wiebe DJ, et al. Maximum daily temperature, precipitation, ultra-violet light and rates of transmission of SARS-Cov-2 in the United States. Clin Infect Dis. 2020 May 30 [Epub ahead of print].Повний текст  Резюме

276. Centre for Evidence-Based Medicine; Heneghan C, Jefferson T. Effect of latitude on COVID-19. 2020 [internet publication].Повний текст

277. Whittemore PB. COVID-19 fatalities, latitude, sunlight, and vitamin D. Am J Infect Control. 2020 Jun 26 [Epub ahead of print].Повний текст  Резюме

278. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Повний текст  Резюме

279. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Повний текст  Резюме

280. Mackey K, Kansagara D, Vela K. Update alert 4: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2020 Sep 22 [Epub ahead of print].Повний текст  Резюме

281. Chan CK, Huang YS, Liao HW, et al. Renin-angiotensin-aldosterone system inhibitors and risks of SARS-CoV-2 infection: a systematic review and meta-analysis. Hypertension. 2020 Sep 1 [Epub ahead of print].Повний текст  Резюме

282. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Jul 31 [Epub ahead of print].Повний текст  Резюме

283. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19. 2020 [internet publication].Повний текст

284. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020 [internet publication].Повний текст

285. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [internet publication].Повний текст

286. British Cardiovascular Society; British Society for Heart Failure. BSH & BCS joint statement on ACEi or ARB in relation to COVID-19. 2020 [internet publication].Повний текст

287. Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020 Aug 1;14(5):1463-5.Повний текст  Резюме

288. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Повний текст  Резюме

289. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020 Aug 12 [Epub ahead of print].Повний текст  Резюме

290. Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020 Aug 4;32(2):176-87.Повний текст  Резюме

291. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020 Aug 25 [Epub ahead of print]. Резюме

292. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2020 Jul 30 [Epub ahead of print].Повний текст  Резюме

293. Costenaro P, Minotti C, Barbieri E, et al. SARS-CoV-2 infection in people living with HIV: a systematic review. Rev Med Virol. 2020 Sep 1:e2155.Повний текст  Резюме

294. Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020 Oct 6;173(7):536-41.Повний текст  Резюме

295. Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020 Jul;19(7):102575.Повний текст  Резюме

296. Favalli EG, Gerosa M, Murgo A, et al. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2020 May 25 [Epub ahead of print].Повний текст  Резюме

297. Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020 Jul 3 [Epub ahead of print].Повний текст  Резюме

298. Liu M, Gao Y, Zhang Y, et al. The association between severe or dead COVID-19 and autoimmune disease: a systematic review and meta-analysis. J Infect. 2020 Sep;81(3):e93-5.Повний текст  Резюме

299. Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020 Sep;2(9):e549-56.Повний текст  Резюме

300. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Jun 26 [Epub ahead of print].Повний текст  Резюме

301. Aziz M, Fatima R, Haghbin H, et al. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 2020 Jul 3 [Epub ahead of print].Повний текст  Резюме

302. Golinelli D, Boetto E, Maietti E, et al. The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. PLoS One. 2020 Sep 18;15(9):e0239508.Повний текст  Резюме

303. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Jun 17 [Epub ahead of print].Повний текст  Резюме

304. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Повний текст  Резюме

305. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 May 19 [Epub ahead of print].Повний текст  Резюме

306. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020 Jun 4 [Epub ahead of print]. Резюме

307. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19) is suspected or confirmed: interim guidance. 2020 [internet publication].Повний текст

308. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ. 2020 Jun 10;369:m2195.Повний текст  Резюме

309. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? 2020 [internet publication].Повний текст

310. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Повний текст  Резюме

311. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2020 [internet publication].Повний текст

312. Centers for Disease Control and Prevention. How to protect yourself and others. 2020 [internet publication].Повний текст

313. Centre for Evidence-Based Medicine; Heneghan C, Jefferson T. COVID-19 evidence is lacking for 2 meter distancing. 2020 [internet publication].Повний текст

314. Feng S, Shen C, Xia N, et al. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med. 2020 May;8(5):434-6.Повний текст  Резюме

315. Mahase E. Covid-19: what is the evidence for cloth masks? BMJ. 2020 Apr 7;369:m1422.Повний текст  Резюме

316. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Jul 20 [Epub ahead of print].Повний текст  Резюме

317. World Health Organization. Advice on the use of masks for children in the community in the context of COVID-19. 2020 [internet publication].Повний текст

318. Centers for Disease Control and Prevention. Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. 2020 [internet publication].Повний текст

319. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Повний текст  Резюме

320. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Повний текст  Резюме

321. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Повний текст  Резюме

322. Centers for Disease Control and Prevention. Serious adverse health events associated with methanol-based hand sanitizers. 2020 [internet publication].Повний текст

323. Mahmood A, Eqan M, Pervez S, et al. COVID-19 and frequent use of hand sanitizers; human health and environmental hazards by exposure pathways. Sci Total Environ. 2020 Jun 27;742:140561.Повний текст  Резюме

324. Quilty BJ, Clifford S, CMMID nCoV working group2, et al. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV). Eurosurveillance. 2020 Feb;25(5).Повний текст

325. Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020 Mar 26;382(13):1278-80.Повний текст  Резюме

326. Kakimoto K, Kamiya H, Yamagishi T, et al. Initial investigation of transmission of COVID-19 among crew members during quarantine of a cruise ship: Yokohama, Japan, February 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):312-3.Повний текст  Резюме

327. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Повний текст  Резюме

328. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Повний текст  Резюме

329. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Apr 8;(4):CD013574.Повний текст  Резюме

330. Centre for Evidence-Based Medicine; Mahtani KR, Heneghan C, Aronson JK. What is the evidence for social distancing during global pandemics? 2020 [internet publication].Повний текст

331. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis. 2020 Jun;20(6):631-3.Повний текст  Резюме

332. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis. 2020 Jun;20(6):678-88.Повний текст  Резюме

333. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2020 [internet publication].Повний текст

334. Mahase E. Covid-19: what do we know so far about a vaccine? BMJ. 2020 Apr 27;369:m1679.Повний текст

335. Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020 Sep 4 [Epub ahead of print].Повний текст  Резюме

336. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 3 [Epub ahead of print].Повний текст  Резюме

337. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 Apr 23;:1-20.Повний текст  Резюме

338. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Jun;20(6):347-8.Повний текст  Резюме

339. Callaway E. Coronavirus vaccine trials have delivered their first results - but their promise is still unclear. Nature. 2020 May;581(7809):363-4.Повний текст  Резюме

340. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-54.Повний текст  Резюме

341. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Jul 20 [Epub ahead of print].Повний текст  Резюме

342. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

343. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Jul 20;:.Повний текст  Резюме

344. AstraZeneca. Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause. 2020 [internet publication].Повний текст

345. AstraZeneca. COVID-19 vaccine AZD1222 clinical trials resumed in the UK. 2020 [internet publication].Повний текст

346. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81.Повний текст  Резюме

347. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

348. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med. 2020 Jul 14 [Epub ahead of print].Повний текст  Резюме

349. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020 Sep 29 [Epub ahead of print].Повний текст  Резюме

350. Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. 2020 Sep 2 [Epub ahead of print].Повний текст  Резюме

351. Mulligan MJ, Lyke KE, Kitchin N, et al; medRxiv. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. 2020 [internet publication].Повний текст

352. US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. 2020 [internet publication].Повний текст

353. World Health Organization. "Immunity passports" in the context of COVID-19: scientific brief. 2020 [internet publication].Повний текст

354. Kofler N, Baylis F. Ten reasons why immunity passports are a bad idea. Nature. 2020 May;581(7809):379-81.Повний текст  Резюме

355. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

356. Department of Health and Social Care. Everyone in the United Kingdom with symptoms now eligible for coronavirus tests. 2020 [internet publication].Повний текст

357. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020 Jul 7;(7):CD013665.Повний текст  Резюме

358. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Повний текст

359. Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020 Jul;179(7):1029-46.Повний текст  Резюме

360. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Повний текст

361. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Повний текст

362. Yang BY, Barnard LM, Emert JM, et al. Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. JAMA Netw Open. 2020 Jul 1;3(7):e2014549.Повний текст  Резюме

363. Centers for Disease Control and Prevention. Ten clinical tips on COVID-19 for healthcare providers involved in patient care. 2020 [internet publication].Повний текст

364. Sommer P, Lukovic E, Fagley E, et al. Initial clinical impressions of the critical care of COVID-19 patients in Seattle, New York City, and Chicago. Anesth Analg. 2020 Jul;131(1):55-60.Повний текст  Резюме

365. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-4.Повний текст  Резюме

366. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020 Apr 30 [Epub ahead of print].Повний текст  Резюме

367. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Clin Infect Dis. 2020 Jun 23 [Epub ahead of print].Повний текст  Резюме

368. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Повний текст  Резюме

369. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Повний текст  Резюме

370. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2020 May 5 [Epub ahead of print].Повний текст  Резюме

371. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Повний текст  Резюме

372. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Повний текст  Резюме

373. Davis B, Rothrock AN, Swetland S, et al. Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis. J Am Coll Emerg Physicians Open. 2020 Jun 19 [Epub ahead of print].Повний текст  Резюме

374. Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 May 27 [Epub ahead of print].Повний текст  Резюме

375. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Jul 22 [Epub ahead of print].Повний текст  Резюме

376. Gayam V, Konala VM, Naramala S, et al. Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. J Med Virol. 2020 May 25 [Epub ahead of print].Повний текст  Резюме

377. Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020 Mar 20 [Epub ahead of print].Повний текст  Резюме

378. Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020 May 16;395(10236):e84.Повний текст  Резюме

379. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol. 2020 Aug 6 [Epub ahead of print].Повний текст  Резюме

380. Li Y, Wang H, Wang F, et al. Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. Int J Infect Dis. 2020 Jun 11;98:80-3.Повний текст  Резюме

381. Cook J, Harman K, Zoica B, et al. Horizontal transmission of severe acute respiratory syndrome coronavirus 2 to a premature infant: multiple organ injury and association with markers of inflammation. Lancet Child Adolesc Health. 2020 Jul;4(7):548-51.Повний текст  Резюме

382. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020 May 11 [Epub ahead of print].Повний текст  Резюме

383. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2020 Sep 10 [Epub ahead of print].Повний текст  Резюме

384. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Резюме

385. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Повний текст  Резюме

386. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Повний текст  Резюме

387. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Повний текст  Резюме

388. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Повний текст  Резюме

389. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Повний текст  Резюме

390. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Повний текст

391. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Повний текст  Резюме

392. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Повний текст  Резюме

393. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Повний текст  Резюме

394. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Повний текст  Резюме

395. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Повний текст  Резюме

396. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Jun 17 [Epub ahead of print].Повний текст  Резюме

397. Public Health England. COVID-19: investigation and initial clinical management of possible cases. 2020 [internet publication].Повний текст

398. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2020 [internet publication].Повний текст

399. American Academy of Pediatrics. COVID-19 testing guidance. 2020 [internet publication].Повний текст

400. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020 Apr 13 [Epub ahead of print].Повний текст  Резюме

401. Williams E, Bond K, Zhang B, et al. Saliva as a non-invasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020 Apr 21 [Epub ahead of print].Повний текст  Резюме

402. Caulley L, Corsten M, Eapen L, et al. Salivary detection of COVID-19. Ann Intern Med. 2020 Aug 28 [Epub ahead of print].Повний текст  Резюме

403. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020 Aug 28 [Epub ahead of print].Повний текст  Резюме

404. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19. 2020 [internet publication].Повний текст

405. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2020 Jun 11 [Epub ahead of print].Повний текст  Резюме

406. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Oct 1 [Epub ahead of print].Повний текст  Резюме

407. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020 Mar 11;26(6).Повний текст  Резюме

408. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020 Oct 1 [Epub ahead of print].Повний текст  Резюме

409. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Повний текст

410. Jefferson T, Spencer E, Brassey J, et al; medRxiv. Viral cultures for COVID-19 infectivity assessment: systematic review. 2020 [internet publication].Повний текст

411. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Повний текст  Резюме

412. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Sep 29 [Epub ahead of print].Повний текст  Резюме

413. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Повний текст  Резюме

414. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Повний текст

415. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2020 [internet publication].Повний текст

416. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Повний текст

417. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Повний текст

418. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

419. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Повний текст  Резюме

420. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2020 [internet publication].Повний текст

421. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Повний текст

422. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Повний текст  Резюме

423. Qu J, Wu C, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Apr 27 [Epub ahead of print].Повний текст  Резюме

424. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Повний текст  Резюме

425. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Повний текст

426. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Повний текст  Резюме

427. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance. 2020 [internet publication].Повний текст

428. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. 2020 [internet publication].Повний текст

429. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020 Feb 6:200274.Повний текст  Резюме

430. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Повний текст

431. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Повний текст  Резюме

432. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Повний текст

433. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Повний текст  Резюме

434. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Feb 27 [Epub ahead of print]. Резюме

435. Tsikala Vafea M, Atalla E, Kalligeros M, et al. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. Clin Radiol. 2020 Aug 12 [Epub ahead of print].Повний текст  Резюме

436. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Повний текст  Резюме

437. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Повний текст  Резюме

438. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 May 30 [Epub ahead of print].Повний текст  Резюме

439. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Mar 12 [Epub ahead of print].Повний текст  Резюме

440. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Jul 21 [Epub ahead of print].Повний текст  Резюме

441. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Повний текст  Резюме

442. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Повний текст  Резюме

443. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Повний текст  Резюме

444. Mohamed MFH, Al-Shokri S, Yousaf Z, et al. Frequency of abnormalities detected by point-of-care lung ultrasound in symptomatic COVID-19 patients: systematic review and meta-analysis. Am J Trop Med Hyg. 2020 Jun 2 [Epub ahead of print].Повний текст  Резюме

445. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Повний текст  Резюме

446. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Повний текст  Резюме

447. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Повний текст  Резюме

448. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Повний текст  Резюме

449. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Повний текст  Резюме

450. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Повний текст  Резюме

451. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Повний текст  Резюме

452. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Apr 8 [Epub ahead of print].Повний текст  Резюме

453. Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 2 [Epub ahead of print]. Резюме

454. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Oct 5 [Epub ahead of print].Повний текст

455. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Повний текст  Резюме

456. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for COVID-19 infection? A prospective case-control study from the United States. Gastroenterology. 2020 May 15 [Epub ahead of print].Повний текст  Резюме

457. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Повний текст  Резюме

458. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020 Jun 4;382(23):2268-70.Повний текст  Резюме

459. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091.Повний текст  Резюме

460. Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2020 Oct 2 [Epub ahead of print].Повний текст  Резюме

461. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Повний текст  Резюме

462. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Aug 26 [Epub ahead of print].Повний текст  Резюме

463. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Sep 16 [Epub ahead of print].Повний текст  Резюме

464. Bataille V, Visconti A, Rossi R, et al; medRxiv. Diagnostic value of skin manifestation of SARS-CoV-2 infection. 2020 [internet publication].Повний текст

465. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Повний текст  Резюме

466. Centers for Disease Control and Prevention. CDC’s diagnostic multiplex assay for flu and COVID-19 and supplies. 2020 [internet publication].Повний текст

467. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Повний текст  Резюме

468. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Повний текст  Резюме

469. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Jun 15 [Epub ahead of print].Повний текст  Резюме

470. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 May 26 [Epub ahead of print].Повний текст  Резюме

471. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Повний текст  Резюме

472. Liu J, Han P, Wu J, et al. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health. 2020 Jun 22 [Epub ahead of print].Повний текст  Резюме

473. Ceriello A. Hyperglycemia and the worse prognosis of COVID-19: why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract. 2020 Apr 29;163:108186.Повний текст  Резюме

474. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020 May 9:1932296820924469.Повний текст  Резюме

475. Iacobellis G, Penaherrera CA, Bermudez LE, et al. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res Clin Pract. 2020 May 1;164:108185.Повний текст  Резюме

476. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Резюме

477. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Повний текст  Резюме

478. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 May 14 [Epub ahead of print]. Резюме

479. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020 Mar 31 [Epub ahead of print].Повний текст  Резюме

480. Aboughdir M, Kirwin T, Abdul Khader A, et al. Prognostic value of cardiovascular biomarkers in COVID-19: a review. Viruses. 2020 May 11;12(5).Повний текст  Резюме

481. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 May 4 [Epub ahead of print].Повний текст  Резюме

482. National Institute for Health and Care Excellence. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. 2020 [internet publication].Повний текст

483. Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med. 2020 May 7 [Epub ahead of print].Повний текст  Резюме

484. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Повний текст  Резюме

485. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Повний текст  Резюме

486. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Повний текст  Резюме

487. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Повний текст  Резюме

488. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Повний текст  Резюме

489. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. 2020 [internet publication].Повний текст

490. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Повний текст

491. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Повний текст  Резюме

492. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Повний текст  Резюме

493. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Aug 14 [Epub ahead of print].Повний текст  Резюме

494. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Повний текст  Резюме

495. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Apr 22 [Epub ahead of print].Повний текст  Резюме

496. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 May 12 [Epub ahead of print].Повний текст  Резюме

497. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Повний текст  Резюме

498. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Повний текст  Резюме

499. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 May 3 [Epub ahead of print].Повний текст  Резюме

500. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020 [internet publication].Повний текст

501. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Повний текст

502. World Health Organization. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. 2020 [internet publication].Повний текст

503. Arima Y, Shimada T, Suzuki M, et al. Severe acute respiratory syndrome coronavirus 2 infection among returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7).Повний текст  Резюме

504. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Повний текст  Резюме

505. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Повний текст

506. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Oct 10 [Epub ahead of print].Повний текст  Резюме

507. Chen G, Xie J, Dai G, et al; medRxiv. Validity of wrist and forehead temperature in temperature screening in the general population during the outbreak of 2019 novel coronavirus: a prospective real-world study. 2020 [internet publication].Повний текст

508. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2020 Oct 2 [Epub ahead of print].Повний текст  Резюме

509. National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. 2020 [internet publication].Повний текст

510. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community. 2020 [internet publication].Повний текст

511. World Health Organization. Corticosteroids for COVID-19: living guidance. 2020 [internet publication].Повний текст

512. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Повний текст  Резюме

513. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2020 [internet publication].Повний текст

514. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (version 1). Ann Intern Med. 2020 Oct 5 [Epub ahead of print].Повний текст  Резюме

515. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Повний текст  Резюме

516. Kilaru AS, Lee K, Snider CK, et al. Return hospital admissions among 1419 covid-19 patients discharged from five US emergency departments. Acad Emerg Med. 2020 Aug 27 [Epub ahead of print].Повний текст  Резюме

517. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Jun 25 [Epub ahead of print].Повний текст  Резюме

518. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Повний текст  Резюме

519. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 Mar 30 [Epub ahead of print].Повний текст  Резюме

520. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Повний текст  Резюме

521. Centers for Disease Control and Prevention. Discontinuation of isolation for persons with COVID-19 not in healthcare settings. 2020 [internet publication].Повний текст

522. Public Health England. Guidance for stepdown of infection control precautions and discharging COVID-19 patients. 2020 [internet publication].Повний текст

523. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020 [internet publication].Повний текст

524. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020 [internet publication].Повний текст

525. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020 Mar 27;368:m1185.Повний текст  Резюме

526. Medicines and Healthcare products Regulatory Agency; Commission on Human Medicines. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19). 2020 [internet publication].Повний текст

527. World Health Organization. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19: scientific brief. 2020 [internet publication].Повний текст

528. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. 2020 [internet publication].Повний текст

529. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2020 Aug 18 [Epub ahead of print].Повний текст  Резюме

530. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 May 20 [Epub ahead of print].Повний текст  Резюме

531. Centers for Disease Control and Prevention. Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (interim guidance). 2020 [internet publication].Повний текст

532. Wilt TJ, Kaka AS, MacDonald R, et al. Remdesivir for adults with COVID-19: a living systematic review for an American College of Physicians practice points. Ann Intern Med. 2020 Oct 5 [Epub ahead of print].Повний текст  Резюме

533. US Food and Drug Administration. COVID-19 update: FDA broadens emergency use authorization for veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. 2020 [internet publication].Повний текст

534. European Medicines Agency. First COVID-19 treatment recommended for EU authorisation. 2020 [internet publication].Повний текст

535. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020 Oct 8 [Epub ahead of print].Повний текст  Резюме

536. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 2020. 2020 [internet publication].Повний текст

537. Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020 Jun 30 [Epub ahead of print].Повний текст  Резюме

538. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Повний текст

539. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854-87.Повний текст  Резюме

540. NHS England. Clinical guide for the optimal use of oxygen therapy during the coronavirus pandemic. 2020 [internet publication].Повний текст

541. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in novel coronavirus disease (COVID-19) patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Apr 21 [Epub ahead of print].Повний текст  Резюме

542. Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic. Acad Emerg Med. 2020 May;27(5):375-8.Повний текст  Резюме

543. Ng Z, Tay WC, Ho CHB. Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients. Eur Respir J. 2020 May 26 [Epub ahead of print].Повний текст  Резюме

544. Golestani-Eraghi M, Mahmoodpoor A. Early application of prone position for management of Covid-19 patients. J Clin Anesth. 2020 May 26;66:109917.Повний текст  Резюме

545. Thompson AE, Ranard BL, Wei Y, et al. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA Intern Med. 2020 Jun 17 [Epub ahead of print].Повний текст  Резюме

546. Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med. 2020 Jun 19 [Epub ahead of print].Повний текст  Резюме

547. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Повний текст  Резюме

548. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Повний текст

549. Public Health England. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Повний текст

550. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 May 21 [Epub ahead of print].Повний текст  Резюме

551. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Jun 2 [Epub ahead of print].Повний текст  Резюме

552. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020 [internet publication].Повний текст

553. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Apr 15 [Epub ahead of print].Повний текст  Резюме

554. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. J Am Coll Cardiol. 2020 Aug 24 [Epub ahead of print].Повний текст  Резюме

555. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Sep 2 [Epub ahead of print].Повний текст  Резюме

556. Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Повний текст  Резюме

557. European Medicines Agency. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. 2020 [internet publication].Повний текст

558. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ. 2020 Jul 30;370:m2924.Повний текст  Резюме

559. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: remdesivir for treating hospitalised patients with suspected or confirmed COVID-19. 2020 [internet publication].Повний текст

560. Canelli R, Connor CW, Gonzalez M, et al. Barrier enclosure during endotracheal intubation. N Engl J Med. 2020 May 14;382(20):1957-8.Повний текст  Резюме

561. Matava CT, Yu J, Denning S. Clear plastic drapes may be effective at limiting aerosolization and droplet spray during extubation: implications for COVID-19. Can J Anaesth. 2020 Apr 3 [Epub ahead of print].Повний текст  Резюме

562. Lucchini A, Giani M, Isgrò S, et al. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation. Intensive Crit Care Nurs. 2020 Apr 2:102859.Повний текст  Резюме

563. Adir Y, Segol O, Kompaniets D, et al. Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy. Eur Respir J. 2020 Apr 20 [Epub ahead of print].Повний текст  Резюме

564. McEnery T, Gough C, Costello RW. COVID-19: respiratory support outside the intensive care unit. Lancet Respir Med. 2020 Apr 9 [Epub ahead of print].Повний текст  Резюме

565. NHS England. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19 (confirmed or suspected). 2020 [internet publication].Повний текст

566. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Повний текст  Резюме

567. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 May 22 [Epub ahead of print].Повний текст  Резюме

568. Thomas R, Lotfi T, Morgano GP, et al. Update alert 2: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Oct 13 [Epub ahead of print].Повний текст  Резюме

569. Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ. 2020 Mar 24;368:m1201.Повний текст  Резюме

570. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020 Jun 6;395(10239):1763-70.Повний текст  Резюме

571. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 Apr 22;323(20):2052-9.Повний текст  Резюме

572. Docherty AB, Harrison EM, Green CA, et al; medRxiv. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. 2020 [internet publication].Повний текст

573. Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020 May 26 [Epub ahead of print].Повний текст  Резюме

574. NHS England. Clinical guide for the management of critical care for adults with COVID-19 during the coronavirus pandemic. 2020 [internet publication].Повний текст

575. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Повний текст  Резюме

576. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Повний текст  Резюме

577. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Apr 14 [Epub ahead of print].Повний текст  Резюме

578. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Apr 24 [Epub ahead of print].Повний текст  Резюме

579. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 Apr 27 [Epub ahead of print].Повний текст  Резюме

580. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Повний текст  Резюме

581. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping ARDS in COVID-19 patients: consequences for ventilator management. Ann Am Thorac Soc. 2020 May 12 [Epub ahead of print].Повний текст  Резюме

582. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Повний текст  Резюме

583. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Apr 22 [Epub ahead of print].Повний текст  Резюме

584. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Повний текст  Резюме

585. Pan C, Chen L, Lu C, et al. Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study. Am J Respir Crit Care Med. 2020 May 15;201(10):1294-7.Повний текст  Резюме

586. Sartini C, Tresoldi M, Scarpellini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA. 2020 May 15 [Epub ahead of print].Повний текст  Резюме

587. Elharrar X, Trigui Y, Dols AM, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA. 2020 May 15 [Epub ahead of print].Повний текст  Резюме

588. American Thoracic Society; Wilson KC, Chotirmall SH, Bai C, et al. COVID‐19: interim guidance on management pending empirical evidence. 2020 [internet publication].Повний текст

589. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Повний текст  Резюме

590. NHS England. Clinical guide for extra corporeal membrane oxygenation (ECMO) for respiratory failure in adults during the coronavirus pandemic. 2020 [internet publication].Повний текст

591. Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

592. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020 Sep 25 [Epub ahead of print].Повний текст  Резюме

593. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11 [Epub ahead of print].Повний текст  Резюме

594. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Повний текст  Резюме

595. Campbell KH, Tornatore JM, Lawrence KE, et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in Southern Connecticut. JAMA. 2020 May 26 [Epub ahead of print].Повний текст  Резюме

596. Fassett MJ, Lurvey LD, Yasumura L, et al. Universal SARS-Cov-2 screening in women admitted for delivery in a large managed care organization. Am J Perinatol. 2020 Jul 3 [Epub ahead of print].Повний текст  Резюме

597. Bianco A, Buckley AB, Overbey J, et al. Testing of patients and support persons for coronavirus disease 2019 (COVID-19) infection before scheduled deliveries. Obstet Gynecol. 2020 May 19 [Epub ahead of print].Повний текст  Резюме

598. Sutton D, Fuchs K, D'Alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020 Apr 13 [Epub ahead of print].Повний текст  Резюме

599. American College of Obstetricians and Gynecologists. Novel coronavirus 2019 (COVID-19). 2020 [internet publication].Повний текст

600. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Mar 3 [Epub ahead of print].Повний текст  Резюме

601. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6. Резюме

602. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2020 [internet publication].Повний текст

603. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2020 [internet publication].Повний текст

604. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2020 Oct 12 [Epub ahead of print].Повний текст  Резюме

605. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Повний текст

606. Centers for Disease Control and Prevention. Evaluation and management considerations for neonates at risk for COVID-19. 2020 [internet publication].Повний текст

607. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): care for breastfeeding women. 2020 [internet publication].Повний текст

608. Kalil AC. Treating COVID-19: off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA Mar 24 [Epub ahead of print].Повний текст  Резюме

609. Marzolini C, Battegay M, Sendi P, et al. Prescribing in COVID-19 patients: should we take into account inflammation? Br J Clin Pharmacol. 2020 Aug 20 [Epub ahead of print].Повний текст  Резюме

610. US Food and Drug Administration. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment, another achievement in administration’s fight against pandemic. 2020 [internet publication].Повний текст

611. Joyner MJ, Senefeld JW, Klassen SA, et al; medRxiv. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. 2020 [internet publication].Повний текст

612. Sarkar S, Soni KD, Khanna P. Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol. 2020 Aug 10 [Epub ahead of print].Повний текст  Резюме

613. Chai KL, Valk SJ, Piechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600.Повний текст  Резюме

614. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020 Jun 15 [Epub ahead of print].Повний текст  Резюме

615. ClinicalTrials.gov. Study assessing the efficacy and safety of anti-spike SARS CoV-2 monoclonal antibodies for prevention of SARS CoV-2 infection asymptomatic in healthy adults who are household contacts to an individual with a positive SARS-CoV-2 RT-PCR assay. 2020 [internet publication].Повний текст

616. Mahase E. Covid-19: RECOVERY trial will evaluate "antiviral antibody cocktail". BMJ. 2020 Sep 15;370:m3584.Повний текст  Резюме

617. Centre for Evidence-Based Medicine; Ferner RE, Aronson JK. Monoclonal antibodies directed against SARS-CoV-2: synthetic neutralizing antibodies, the REGN-COV2 antibody cocktail. 2020 [internet publication].Повний текст

618. ClinicalTrials.gov. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate covid-19 illness (BLAZE-1). 2020 [internet publication].Повний текст

619. Eli Lilly and Company. Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs. 2020 [internet publication].Повний текст

620. AstraZeneca. COVID-19 long-acting antiBody (LAAB) combination AZD7442 rapidly advances into phase III clinical trials. 2020 [internet publication].Повний текст

621. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-71.Повний текст  Резюме

622. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-83.Повний текст  Резюме

623. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949.Повний текст  Резюме

624. Chen Z, Hu J, Zhang Z, et al; medRxiv. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. 2020 [internet publication].Повний текст

625. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849.Повний текст  Резюме

626. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020 May 27 [Epub ahead of print].Повний текст  Резюме

627. Hernandez AV, Roman YM, Pasupuleti V, et al. Update alert 2: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Ann Intern Med. 2020 Aug 27 [Epub ahead of print].Повний текст  Резюме

628. Pathak DSK, Salunke DAA, Thivari DP, et al. No benefit of hydroxychloroquine in COVID-19: results of systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2020 Sep 1;14(6):1673-80.Повний текст  Резюме

629. Ladapo JA, McKinnon JE, McCullough PA, et al; medRxiv. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. 2020 [internet publication].Повний текст

630. Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so used early, for Covid-19: a systematic review. New Microbes New Infect. 2020 Oct 5:100776.Повний текст  Резюме

631. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. 2020 Sep 30 [Epub ahead of print].Повний текст  Резюме

632. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Oct 8 [Epub ahead of print].Повний текст  Резюме

633. Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020 Jun 16;141(24):e906-7.Повний текст  Резюме

634. Kamp TJ, Hamdan MH, January CT. Chloroquine or hydroxychloroquine for COVID-19: is cardiotoxicity a concern? J Am Heart Assoc. 2020 May 28:e016887.Повний текст  Резюме

635. Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020 May 1 [Epub ahead of print].Повний текст  Резюме

636. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1 [Epub ahead of print].Повний текст  Резюме

637. Nguyen LS, Dolladille C, Drici MD, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation. 2020 May 22 [Epub ahead of print].Повний текст  Резюме

638. TLC. TLC receives Australian and Taiwan approval to initiate phase I clinical trial of TLC19 inhalable liposomal hydroxychloroquine for COVID-19. 2020 [internet publication].Повний текст

639. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3;323(15):1488-94.Повний текст  Резюме

640. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 May 7;382(19):1787-99.Повний текст  Резюме

641. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5 [Epub ahead of print].Повний текст  Резюме

642. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. 2020 [internet publication].Повний текст

643. Beyls C, Martin N, Hermida A, et al. Lopinavir-ritonavir treatment for COVID-19 infection in intensive care unit: risk of bradycardia. Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798.Повний текст  Резюме

644. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020 Mar 25;21(7).Повний текст  Резюме

645. Xie Y, Cao S, Li Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020 Apr 10 [Epub ahead of print].Повний текст  Резюме

646. Zhang J, Yang Y, Yang N, et al. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review. Ann Transl Med. 2020 May;8(10):625.Повний текст  Резюме

647. Aziz M, Haghbin H, Sitta EA, et al. Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis. J Med Virol. 2020 Sep 12 [Epub ahead of print].Повний текст  Резюме

648. Genentech. Genentech’s phase III EMPACTA study showed Actemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with COVID-19 associated pneumonia. 2020 [internet publication].Повний текст

649. Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatol. 2020 Sep 9 [Epub ahead of print].Повний текст  Резюме

650. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun;2(6):e325-31.Повний текст  Резюме

651. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020 Jul;2(7):e393-400.Повний текст  Резюме

652. Navarro-Millán I, Sattui SE, Lakhanpal A, et al. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheumatol. 2020 Jun 30 [Epub ahead of print].Повний текст  Резюме

653. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Повний текст

654. Mahase E. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community. BMJ. 2020 Oct 1;371:m3847.Повний текст  Резюме

655. De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e465-73.Повний текст  Резюме

656. Temesgen Z, Assi M, Shweta FNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-control study. Mayo Clin Proc. 2020 Aug [Epub ahead of print].Повний текст

657. Temesgen Z, Assi M, Vergidis P, et al. First clinical use of lenzilumab to neutralize GM-CSF in patients with severe COVID-19 pneumonia. medRxiv. 2020 Jun 14 [Epub ahead of print].Повний текст  Резюме

658. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Jun;53(3):368-70.Повний текст  Резюме

659. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137-46.Повний текст  Резюме

660. Titanji BK, Farley MM, Mehta A, et al. Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis. 2020 Jun 29 [Epub ahead of print].Повний текст  Резюме

661. Eli Lilly and Company. Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial. 2020 [internet publication].Повний текст

662. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Повний текст

663. Cheng LL, Guan WJ, Duan CY, et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial. JAMA Intern Med. 2020 Sep 10 [Epub ahead of print].Повний текст  Резюме

664. Centre for Evidence-Based Medicine; Soliman R, Brassey J, Plüddemann A, et al. Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence. 2020 [internet publication].Повний текст

665. World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief. 2020 [internet publication].Повний текст

666. Department of Health and Social Care. COVID-19 treatments could be fast-tracked through new national clinical trial initiative. 2020 [internet publication].Повний текст

667. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4 [Epub ahead of print].Повний текст  Резюме

668. ClinicalTrials.gov. Losartan for patients with COVID-19 requiring hospitalization. 2020 [internet publication].Повний текст

669. ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. 2020 [internet publication].Повний текст

670. Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020 Sep 24;17(1):141.Повний текст  Резюме

671. Huang D, Yu H, Wang T, et al. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020 Jul 3 [Epub ahead of print].Повний текст  Резюме

672. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-704.Повний текст  Резюме

673. National Institutes of Health. NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins. 2020 [internet publication].Повний текст

674. University of Oxford. PRINCIPLE trial. 2020 [internet publication].Повний текст

675. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Повний текст  Резюме

676. Momekov G, Momekova D; medRxiv. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. 2020 [internet publication].Повний текст

677. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Повний текст  Резюме

678. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Повний текст

679. Baladia E, Pizarro AB, Ortiz-Muñoz L, et al. Vitamin C for COVID-19: a living systematic review. Medwave. 2020 Jul 28;20(6):e7978.Повний текст  Резюме

680. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Повний текст  Резюме

681. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Повний текст  Резюме

682. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Повний текст  Резюме

683. ClinicalTrials.gov. Vitamin D on prevention and treatment of COVID-19 (COVITD-19). 2020 [internet publication].Повний текст

684. ClinicalTrials.gov. COVID-19 and vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients (CoVitTrial). 2020 [internet publication].Повний текст

685. Centre for Evidence-Based Medicine; Lee J, van Hecke O, Roberts N. Vitamin D: a rapid review of the evidence for treatment or prevention in COVID-19. 2020 [internet publication].Повний текст

686. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Повний текст  Резюме

687. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: vitamin D for COVID-19. 2020 [internet publication].Повний текст

688. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: authors' reply. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):722-3.Повний текст  Резюме

689. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020 Mar 15;16(10):1708-17.Повний текст  Резюме

690. Harch PG. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res. Apr-Jun 2020;10(2):61-2. Резюме

691. Thibodeaux K, Speyrer M, Raza A, et al. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020 May 1;29(sup5a):S4-8. Резюме

692. ClinicalTrials.gov. Hyperbaric oxygen for COVID-19 patients. 2020 [internet publication].Повний текст

693. ClinicalTrials.gov. Safety and efficacy of hyperbaric oxygen for ARDS in patients with COVID-19 (COVID-19-HBO). 2020 [internet publication].Повний текст

694. Martel J, Ko YF, Young JD, et al. Could nasal nitric oxide help to mitigate the severity of COVID-19? Microbes Infect. 2020 May 6 [Epub ahead of print].Повний текст  Резюме

695. ClinicalTrials.gov. Intravenous aviptadil for critical COVID-19 with respiratory failure (COVID-AIV). 2020 [internet publication].Повний текст

696. ClinicalTrials.gov. Inhaled aviptadil for the treatment of non-acute lung injury in COVID-19 (AVINALI). 2020 [internet publication].Повний текст

697. NeuroRx. NeuroRx submits request for emergency use authorization for RLF-100™ (aviptadil) in the treatment of patients with critical COVID-19 and respiratory failure who have exhausted approved therapy. 2020 [internet publication].Повний текст

698. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020 Aug 3;3(8):e2017708.Повний текст  Резюме

699. Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals' interim analysis from ODYSSEY study shows tradipitant may accelerate clinical improvement in patients with COVID-19 pneumonia. 2020 [internet publication].Повний текст

700. ClinicalTrials.gov. ODYSSEY: a study to investigate the efficacy of tradipitant in treating severe or critical COVID-19 infection. 2020 [internet publication].Повний текст

701. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Повний текст  Резюме

702. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Jul 31 [Epub ahead of print].Повний текст  Резюме

703. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Повний текст  Резюме

704. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur J Clin Invest. 2020 Oct 7:e13421.Повний текст  Резюме

705. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. Int J Infect Dis. 2020 Sep 29 [Epub ahead of print].Повний текст  Резюме

706. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Повний текст  Резюме

707. Department of Health and Social Care. UK Biobank COVID-19 antibody study: round 1 results. 2020 [internet publication].Повний текст

708. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020 Jun 5 [Epub ahead of print].Повний текст  Резюме

709. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological updates. 2020 [internet publication].Повний текст

710. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Повний текст  Резюме

711. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Повний текст  Резюме

712. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Повний текст  Резюме

713. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Повний текст  Резюме

714. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Повний текст  Резюме

715. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Повний текст

716. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Повний текст  Резюме

717. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Повний текст

718. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Повний текст

719. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 Mar 23 [Epub ahead of print].Повний текст  Резюме

720. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in Covid-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020 Jul 29:e13362.Повний текст  Резюме

721. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Повний текст  Резюме

722. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Повний текст  Резюме

723. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2020 Sep 8 [Epub ahead of print]. Резюме

724. Parry J. Covid-19: Hong Kong scientists report first confirmed case of reinfection. BMJ. 2020 Aug 26;370:m3340.Повний текст  Резюме

725. Gupta V, Bhoyar RC, Jain A, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin Infect Dis. 2020 Sep 23 [Epub ahead of print].Повний текст  Резюме

726. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al; SSRN. COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America. 2020 [internet publication].Повний текст

727. Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020 Sep 5 [Epub ahead of print].Повний текст  Резюме

728. Larson D, Brodniak SL, Voegtly LJ, et al. A case of early re-infection with SARS-CoV-2. Clin Infect Dis. 2020 Sep 19 [Epub ahead of print].Повний текст  Резюме

729. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020 Oct 12 [Epub ahead of print].Повний текст

730. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020 Sep 1 [Epub ahead of print].Повний текст  Резюме

731. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 May 20 [Epub ahead of print].Повний текст  Резюме

732. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020 May 11 [Epub ahead of print].Повний текст  Резюме

733. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020 Jun 16;52(6):971-7.Повний текст  Резюме

734. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Sep 11 [Epub ahead of print].Повний текст  Резюме

735. Wajnberg A, Mansour M, Leven E, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020 Sep 25 [Epub ahead of print].Повний текст  Резюме

736. Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020 Aug 18 [Epub ahead of print].Повний текст  Резюме

737. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Jun 18 [Epub ahead of print].Повний текст  Резюме

738. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Повний текст  Резюме

739. Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 Jul 9 [Epub ahead of print].Повний текст  Резюме

740. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Повний текст

741. Lu YF, Pan LY, Zhang WW, et al. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020 Aug 13 [Epub ahead of print].Повний текст  Резюме

742. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Повний текст  Резюме

743. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients With COVID-19 in a New York City health system. JAMA. 2020 Jul 20 [Epub ahead of print].Повний текст  Резюме

744. Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 May 11;7(6):e438-40.Повний текст  Резюме

745. American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. 2020 [internet publication].Повний текст

746. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020 May 13;192:23-6.Повний текст  Резюме

747. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020 May 6 [Epub ahead of print].Повний текст  Резюме

748. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-3.Повний текст  Резюме

749. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38.Повний текст  Резюме

750. Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020 Jul 16;383(3):288-90.Повний текст  Резюме

751. Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020 Aug;192:113-5.Повний текст  Резюме

752. Xiao M, Zhang Y, Zhang S, et al. Brief report: anti-phospholipid antibodies in critically ill patients with coronavirus disease 2019 (COVID-19). Arthritis Rheumatol. 2020 Jun 30 [Epub ahead of print].Повний текст  Резюме

753. Reyes Gil M, Barouqa M, Szymanski J, et al. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020 Aug 3;3(8):e2017539.Повний текст  Резюме

754. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Повний текст  Резюме

755. McGonagle D, O'Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020 Jul;2(7):e437-45.Повний текст  Резюме

756. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Повний текст  Резюме

757. Perini P, Nabulsi B, Massoni CB, et al. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet. 2020 May 16;395(10236):1546.Повний текст  Резюме

758. Griffin DO, Jensen A, Khan M, et al. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Br J Haematol. 2020 Jul;190(1):e11-3.Повний текст  Резюме

759. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14.Повний текст  Резюме

760. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol. 2020 Jun;189(6):1053-4.Повний текст  Резюме

761. Hemasian H, Ansari B. First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev Neurol (Paris). 2020 Jun;176(6):521-3.Повний текст  Резюме

762. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Mar 27 [Epub ahead of print].Повний текст  Резюме

763. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Повний текст  Резюме

764. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 May 19;141(20):1648-55.Повний текст  Резюме

765. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Повний текст  Резюме

766. Zou F, Qian Z, Wang Y, et al. Cardiac injury and COVID-19: a systematic review and meta-analysis. CJC Open. 2020 Jun 23 [Epub ahead of print].Повний текст  Резюме

767. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Повний текст  Резюме

768. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Повний текст  Резюме

769. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Повний текст  Резюме

770. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Повний текст  Резюме

771. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Повний текст  Резюме

772. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Повний текст  Резюме

773. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Повний текст  Резюме

774. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25;5(7):802-10.Повний текст  Резюме

775. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 15;48(0):E011. Резюме

776. Santoso A, Pranata R, Wibowo A, et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020 Apr 19 [Epub ahead of print].Повний текст  Резюме

777. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 May 14;41(19):1821-9.Повний текст  Резюме

778. National Institute for Health and Care Excellence. COVID-19 rapid guideline: acute myocardial injury. 2020 [internet publication].Повний текст

779. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 May 5 [Epub ahead of print].Повний текст  Резюме

780. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Повний текст  Резюме

781. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 27 [Epub ahead of print].Повний текст  Резюме

782. Fu EL, Janse RJ, de Jong Y, et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin Kidney J. 2020 Sep 2;13(4):550-63.Повний текст  Резюме

783. Stewart DJ, Hartley JC, Johnson M, et al. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health. 2020 Jun 15;4(8):e28-9.Повний текст  Резюме

784. National Institute for Health and Care Excellence. COVID-19 rapid guideline: acute kidney injury in hospital. 2020 [internet publication].Повний текст

785. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020 May 5 [Epub ahead of print].Повний текст  Резюме

786. Nasr SH, Kopp JB. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int Rep. 2020 May 4;5(6):759-61.Повний текст  Резюме

787. Gross O, Moerer O, Weber M, et al. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020 May 16;395(10236):e87-8.Повний текст  Резюме

788. Kunutsor SK, Laukkanen JA. Hepatic manifestations and complications of COVID-19: a systematic review and meta-analysis. J Infect. 2020 Jun 21 [Epub ahead of print].Повний текст  Резюме

789. Wijarnpreecha K, Ungprasert P, Panjawatanan P, et al. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2020 Jul 3 [Epub ahead of print]. Резюме

790. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Повний текст  Резюме

791. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Повний текст  Резюме

792. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 Apr 10;77(6):1-9.Повний текст  Резюме

793. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020 Jun 1 [Epub ahead of print].Повний текст  Резюме

794. Kandemirli SG, Dogan L, Sarikaya ZT, et al. Brain MRI findings in patients in the intensive care unit with COVID-19 infection. Radiology. 2020 May 8:201697.Повний текст  Резюме

795. Panda PK, Sharawat IK, Panda P, et al. Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Sep 10 [Epub ahead of print].Повний текст  Резюме

796. Orrù G, Conversano C, Malloggi E, et al. Neurological complications of COVID-19 and possible neuroinvasion pathways: a systematic review. Int J Environ Res Public Health. 2020 Sep 14;17(18):E6688.Повний текст  Резюме

797. Restivo DA, Centonze D, Alesina A, et al. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020 Aug 10 [Epub ahead of print].Повний текст  Резюме

798. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2020 Aug 25 [Epub ahead of print].Повний текст  Резюме

799. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Повний текст  Резюме

800. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Повний текст  Резюме

801. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Jul 9 [Epub ahead of print].Повний текст  Резюме

802. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Повний текст  Резюме

803. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug 3 [Epub ahead of print].Повний текст  Резюме

804. COVID Symptom Study. How long does COVID-19 last? 2020 [internet publication].Повний текст

805. Mahase E. Covid-19: what do we know about “long covid”? BMJ. 2020 Jul 14;370:m2815.Повний текст  Резюме

806. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network: United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8.Повний текст  Резюме

807. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Повний текст  Резюме

808. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Повний текст  Резюме

809. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13:101623.Повний текст  Резюме

810. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Повний текст  Резюме

811. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-7.Повний текст  Резюме

812. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Повний текст  Резюме

813. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Повний текст  Резюме

814. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Повний текст  Резюме

815. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `'cytokine storm' in COVID-19. J Infect. 2020 Jun;80(6):607-13.Повний текст  Резюме

816. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16 [Epub ahead of print].Повний текст  Резюме

817. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020 Apr 28 [Epub ahead of print].Повний текст  Резюме

818. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020 May 1;130(5):2202-5.Повний текст  Резюме

819. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020 Mar 25:108393.Повний текст  Резюме

820. Pain CE, Felsenstein S, Cleary G, et al. Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatol. 2020 May 15;2(7):e376-9.Повний текст  Резюме

821. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: a systematic review. J Pediatr. 2020 Aug 5 [Epub ahead of print].Повний текст  Резюме

822. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19–associated multisystem inflammatory syndrome in children: United States, March–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-80.Повний текст  Резюме

823. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020 Aug 17 [Epub ahead of print].Повний текст  Резюме

824. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [internet publication].Повний текст

825. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 [internet publication].Повний текст

826. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2020 Aug 11 [Epub ahead of print].Повний текст  Резюме

827. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020 Jul 9 [Epub ahead of print].Повний текст  Резюме

828. Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020 Sep 18 [Epub ahead of print].Повний текст  Резюме

829. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. 2020 Jul 23 [Epub ahead of print].Повний текст  Резюме

830. Shulman ST. Pediatric coronavirus disease-2019-associated multisystem inflammatory syndrome. J Pediatric Infect Dis Soc. 2020 Jul 13;9(3):285-6.Повний текст  Резюме

831. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020 Aug 18 [Epub ahead of print].Повний текст  Резюме

832. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection: United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 9 [Epub ahead of print].Повний текст  Резюме

833. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2020 Aug 28 [Epub ahead of print].Повний текст  Резюме

834. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun;63(6):528-34.Повний текст  Резюме

835. Blaize M, Mayaux J, Nabet C, et al. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis. 2020 Apr 28;26(7).Повний текст  Резюме

836. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al. COVID-19 associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020 May 12 [Epub ahead of print].Повний текст  Резюме

837. Alanio A, Dellière S, Fodil S, et al. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020 Jun;8(6):e48-9.Повний текст  Резюме

838. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Повний текст  Резюме

839. Verweij PE, Gangneux JP, Bassetti M, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020 Jun;1(2):e53-5.Повний текст  Резюме

840. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Повний текст  Резюме

841. Bruno G, Fabrizio C, Santoro CR, et al. Pancreatic injury in the course of coronavirus disease 2019: a not-so-rare occurrence. J Med Virol. 2020 Jun 4 [Epub ahead of print].Повний текст  Резюме

842. McNabb-Baltar J, Jin DX, Grover AS, et al. Lipase elevation in patients with COVID-19. Am J Gastroenterol. 2020 Jun 3 [Epub ahead of print].Повний текст  Резюме

843. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2020 Jun 3 [Epub ahead of print].Повний текст  Резюме

844. Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020 Jul;190(1):29-31.Повний текст  Резюме

845. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Повний текст  Резюме

846. Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020 Jul 30 [Epub ahead of print].Повний текст  Резюме

847. Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa276.Повний текст  Резюме

848. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24 [Epub ahead of print].Повний текст  Резюме

849. Centre for Evidence-Based Medicine; Greenhalgh T, Treadwell J, Burrow R, et al. NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care? 2020 [internet publication].Повний текст

850. NHS England. After-care needs of inpatients recovering from COVID-19. 2020 [internet publication].Повний текст

851. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Aug 24 [Epub ahead of print].Повний текст  Резюме

852. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Jul 16 [Epub ahead of print].Повний текст  Резюме

853. Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020 May 1;48(8):e657-65.Повний текст  Резюме

854. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020 Apr 9 [Epub ahead of print].Повний текст  Резюме

855. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 May 12 [Epub ahead of print].Повний текст  Резюме

856. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open. 2020 Sep 25;10(9):e040729.Повний текст  Резюме

857. Yadaw AS, Li YC, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health. 2020 Oct;2(10):e516-25.Повний текст  Резюме

858. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020 Sep 9;370:m3339.Повний текст  Резюме

859. Centers for Disease Control and Prevention. Interim guidance for public health professionals managing people with COVID-19 in home care and isolation who have pets or other animals. 2020 [internet publication].Повний текст

860. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): COVID-19 and animals. 2020 [internet publication].Повний текст

861. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020 May 29;368(6494):1016-20.Повний текст  Резюме

862. IDEXX Laboratories. Leading veterinary diagnostic company sees no COVID-19 cases in pets. 2020 [internet publication].Повний текст

863. Newman A, Smith D, Ghai RR, et al. First reported cases of SARS-CoV-2 infection in companion animals: New York, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):710-3.Повний текст  Резюме

864. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med. 2020 Aug 6 [Epub ahead of print].Повний текст  Резюме

865. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): if you have pets. 2020 [internet publication].Повний текст

866. Phelan D, Kim JH, Chung EH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. JAMA Cardiol. 2020 May 13 [Epub ahead of print].Повний текст  Резюме

867. American Academy of Pediatrics. COVID-19 interim guidance: return to sports. 2020 [internet publication].Повний текст

Використання цього контенту підпадає під нашу відмову від відповідальності